Clinical effect of combination therapy of pioglitazone and an α-glucosidase inhibitor

被引:12
作者
Seino, H
Yamaguchi, H
Misaki, A
Sakata, Y
Kitagawa, M
Yamazaki, T
Kikuchi, H
Abe, R
机构
[1] Nishi Ohtsu Hosp, Internal Med Diabetes Ctr, Fukushima 9638558, Japan
[2] Ohta Kinen Hosp, Fukushima 9638004, Japan
关键词
body fat; diabetes; leptin; pioglitazone; tumour necrosis factor-alpha (TNF-alpha);
D O I
10.1185/030079903125002423
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This study evaluated the efficacy of adding pioglitazone 30 mg to the therapy of patients with type 2 diabetes mellitus whose glycaemic control was poor on an alpha-glucosidase inhibitor (alpha-GI) alone or in combination with a sulphonylurea (SU). The patients (n = 20) had a HbA(1c) level between 7.0 and 12.0% and the fasting plasma glucose was 7.8 mmol/l or higher. They were treated with 30 mg pioglitazone once daily for 16 weeks. The decrease in HbA(1c) at week 16 of treatment was 0.8% (7.8% at baseline dropping to 7.1% at week 16; p less than or equal to 0.01). An increase in leptin was observed 4 weeks after starting the post-study period (p less than or equal to 0.05). Tumour necrosis factor-alpha (TNF-alpha) and body fat percentage did not show significant alterations. Correlations between the decrease in HbA(1c) at week 16 and characteristic variables of patients were examined. A correlation with leptin (p = -0.5632, p less than or equal to 0.05) levels was found. Five patients experienced adverse drug reactions, such as oedema, hypoglycaemia and increased creatine phosphokinase (CK), all of which were mild in severity. The addition of pioglitazone in diabetics whose glycaemic control was poor on a alpha-GI alone or with a alpha-GI and SU combination resulted in a significant decrease in HbA(1c), and the treatment was well-tolerated. Our findings also suggest that leptin levels could be useful for assessing responders to pioglitazone.
引用
收藏
页码:675 / 682
页数:8
相关论文
共 27 条
[1]   Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study [J].
Aronoff, S ;
Rosenblatt, S ;
Braithwaite, S ;
Egan, JW ;
Mathisen, AL ;
Schneider, RL .
DIABETES CARE, 2000, 23 (11) :1605-1611
[2]   PPARγ, the ultimate thrifty gene [J].
Auwerx, J .
DIABETOLOGIA, 1999, 42 (09) :1033-1049
[3]   Pioglitazone: A review of Japanese clinical studies [J].
Baba, S .
CURRENT MEDICAL RESEARCH AND OPINION, 2001, 17 (03) :166-189
[4]  
Balfour JAB, 1999, DRUGS, V57, P921
[5]   Troglitazone: An antidiabetic agent (Reprinted) [J].
Chen, C .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (09) :905-925
[6]   RELATIONSHIP OF BODY-FAT TOPOGRAPHY TO INSULIN SENSITIVITY AND METABOLIC PROFILES IN PREMENOPAUSAL WOMEN [J].
EVANS, DJ ;
HOFFMANN, RG ;
KALKHOFF, RK ;
KISSEBAH, AH .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1984, 33 (01) :68-75
[7]   15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2) IS A LIGAND FOR THE ADIPOCYTE DETERMINATION FACTOR PPAR-GAMMA [J].
FORMAN, BM ;
TONTONOZ, P ;
CHEN, J ;
BRUN, RP ;
SPIEGELMAN, BM ;
EVANS, RM .
CELL, 1995, 83 (05) :803-812
[8]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[9]   Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats [J].
Hayakawa, T ;
Shiraki, T ;
Morimoto, T ;
Shii, K ;
Ikeda, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1996, 223 (02) :439-444
[10]   IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance [J].
Hotamisligil, GS ;
Peraldi, P ;
Budavari, A ;
Ellis, R ;
White, MF ;
Spiegelman, BM .
SCIENCE, 1996, 271 (5249) :665-668